Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del<i>CFTR</i>Claire Wainwright, Michael Boyle, J.S. Elborn et al.|New England Journal of Medicine|2015Cited by 1.6k
Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> MutationFrank J. Accurso, Bonnie W. Ramsey, Steven M. Rowe et al.|New England Journal of Medicine|2010Cited by 802
Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutationJohn P. Clancy, Michael W. Konstan, Steven M. Rowe et al.|Thorax|2011Cited by 496
A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trialMichael Boyle, David M. Rodman, Scott C. Bell et al.|The Lancet Respiratory Medicine|2014Cited by 442
Risk Factors For Rate of Decline in Forced Expiratory Volume in One Second in Children and Adolescents with Cystic FibrosisMichael W. Konstan, Charles A. Johnson, Jeffrey S. Wagener et al.|The Journal of Pediatrics|2007Cited by 441